{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:53:24Z","timestamp":1793307204781,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002411","name":"Universidad Icesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.vhri.2022.08.002","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T18:57:53Z","timestamp":1664477873000},"page":"109-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Cost-Effectiveness Analysis of Pertuzumab Plus Trastuzumab and Docetaxel Compared With Trastuzumab and Docetaxel in the Adjuvant Treatment of Human Epidermal Growth Factor Receptor 2\u2013Positive Metastatic Breast Cancer in Colombia"],"prefix":"10.1016","volume":"32","author":[{"given":"C\u00e9sar Augusto","family":"Guevara-Cuellar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Parody-R\u00faa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Paula","family":"Rengifo-Mosquera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"del Mar Conde-Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhon Maicol","family":"Nu\u00f1ez-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vhri.2022.08.002_bib1","author":"Jimenez Herrera"},{"issue":"2","key":"10.1016\/j.vhri.2022.08.002_bib2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.rccan.2016.02.003","article-title":"Direct costs of breast cancer care in Colombia","volume":"20","author":"Gamboa","year":"2016","journal-title":"Rev Colomb Cancerol"},{"issue":"11","key":"10.1016\/j.vhri.2022.08.002_bib3","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.trecan.2017.09.001","article-title":"Breast cancer: multiple subtypes within a tumor?","volume":"3","author":"Yeo","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1016\/j.vhri.2022.08.002_bib4","author":"Fletscher Covaleda"},{"issue":"2","key":"10.1016\/j.vhri.2022.08.002_bib7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10549-018-05099-3","article-title":"An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer","volume":"174","author":"Gogate","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"10.1016\/j.vhri.2022.08.002_bib8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (Cleopatra): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.vhri.2022.08.002_bib11","doi-asserted-by":"crossref","first-page":"A631","DOI":"10.1016\/j.jval.2014.08.2258","article-title":"Cost-effectiveness model of pertuzumab in combination with trastuzumab and docetaxel compared with trastuzumab in combination with docetaxel for the 1st line treatment of HER2+ metastatic breast cancer in Colombia","volume":"17","author":"Saenz","year":"2014","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.vhri.2022.08.002_bib16","first-page":"173","article-title":"Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada","volume":"18","author":"Attard","year":"2015","journal-title":"J\u00a0Med Econ"},{"issue":"1","key":"10.1016\/j.vhri.2022.08.002_bib17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10549-020-05587-5","article-title":"Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes","volume":"181","author":"Hassett","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.vhri.2022.08.002_bib18","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","article-title":"Partitioned survival and state transition models for healthcare decision making in oncology: where are we now?","volume":"23","author":"Woods","year":"2020","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.vhri.2022.08.002_bib19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/14737167.2021.1893167","article-title":"Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments","volume":"21","author":"Rui","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.vhri.2022.08.002_bib20","author":"Rohatgi"},{"key":"10.1016\/j.vhri.2022.08.002_bib24","author":"Le\u00f3n Guzm\u00e1n"},{"issue":"3","key":"10.1016\/j.vhri.2022.08.002_bib25","doi-asserted-by":"crossref","first-page":"255","DOI":"10.17533\/udea.iatreia.v30n3a01","article-title":"Comparison of three bioimpedance techniques with hydrodensitometry for assessment of body composition in young adult women","volume":"30","author":"Aristiz\u00e1bal","year":"2017","journal-title":"Iatreia"},{"issue":"2","key":"10.1016\/j.vhri.2022.08.002_bib26","doi-asserted-by":"crossref","first-page":"154","DOI":"10.25100\/cm.v49i2.3643","article-title":"Development and validation of anthropometric equations to estimate body composition in adult women","volume":"49","author":"Aristizabal","year":"2018","journal-title":"Colomb Med"},{"issue":"3","key":"10.1016\/j.vhri.2022.08.002_bib27","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.rccan.2018.09.002","article-title":"Caracter\u00edsticas y supervivencia de pacientes con c\u00e1ncer de seno metast\u00e1sico HER2-positivo en la era post-trastuzumab","volume":"22","author":"Montoya-Restrepo","year":"2018","journal-title":"Rev Colomb Cancerol"},{"issue":"5","key":"10.1016\/j.vhri.2022.08.002_bib28","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/annonc\/mdu053","article-title":"Which threshold for ER positivity? a retrospective study based on 9639 patients","volume":"25","author":"Yi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.vhri.2022.08.002_bib29","article-title":"Management costs of febrile neutropenia in oncology patients in Colombia","author":"Lema","year":"2021","journal-title":"Research Square"},{"issue":"7","key":"10.1016\/j.vhri.2022.08.002_bib30","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.vhri.2022.08.002_bib31","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.vhri.2022.08.002_bib32","first-page":"1","article-title":"survHE: Survival Analysis fo Health Economic Evaluation and Cost-Effectiveness Modeling","volume":"95","author":"Baio","year":"2020","journal-title":"J\u00a0Stat Soft"},{"issue":"3","key":"10.1016\/j.vhri.2022.08.002_bib34","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/heapol\/czab146","article-title":"Estimating cost-effectiveness thresholds under a managed healthcare system: experiences from Colombia","volume":"37","author":"Espinosa","year":"2022","journal-title":"Health Policy Plan"},{"issue":"3","key":"10.1016\/j.vhri.2022.08.002_bib35","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/14737167.2021.1880323","article-title":"Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore","volume":"21","author":"Cheng","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"3","key":"10.1016\/j.vhri.2022.08.002_bib36","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s41669-020-00254-3","article-title":"Economic evaluation of first-line pertuzumab therapy in patients with HER2-positive metastatic breast cancer in Japan","volume":"5","author":"Moriwaki","year":"2021","journal-title":"Pharmacoecon Open"},{"issue":"9","key":"10.1016\/j.vhri.2022.08.002_bib37","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1200\/JCO.2015.62.9105","article-title":"Cost-effectiveness of pertuzumab in human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"34","author":"Durkee","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"15 suppl","key":"10.1016\/j.vhri.2022.08.002_bib38","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1200\/JCO.2021.39.15_suppl.1048","volume":"39","author":"Dai","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.vhri.2022.08.002_bib39","first-page":"514","article-title":"Cancer immunotherapy, part 3: challenges and future trends","volume":"42","author":"Ventola","year":"2017","journal-title":"P\u00a0T"},{"key":"10.1016\/j.vhri.2022.08.002_bib40","series-title":"Care at the End of Life: an Economic Perspective","first-page":"155","article-title":"Does society place special value on end of life treatments?","author":"Shah","year":"2016"},{"issue":"8","key":"10.1016\/j.vhri.2022.08.002_bib41","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s40273-017-0511-7","article-title":"Does the public prefer health gain for cancer patients? A systematic review of public views on cancer and its characteristics","volume":"35","author":"Morrell","year":"2017","journal-title":"Pharmacoeconomics"},{"issue":"377","key":"10.1016\/j.vhri.2022.08.002_bib42","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2307\/2233468","article-title":"The value of safety: results of a national sample survey","volume":"95","author":"Jones-Lee","year":"1985","journal-title":"Econ J"},{"issue":"3","key":"10.1016\/j.vhri.2022.08.002_bib43","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1743-7563.2012.01546.x","article-title":"Evaluation of the willingness-to-pay for cancer treatment in Korean metastatic breast cancer patients: a multicenter, cross-sectional study","volume":"8","author":"Oh","year":"2012","journal-title":"Asia Pac J Clin Oncol"},{"issue":"3","key":"10.1016\/j.vhri.2022.08.002_bib44","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/jjco\/hyaa241","article-title":"Prospective observational study estimating willingness-to-pay for breast cancer treatments through contingent valuation method in Japanese breast cancer patients (JCOG1709A)","volume":"51","author":"Iwatani","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.vhri.2022.08.002_bib45","article-title":"Democracy, culture and cancer patients\u2019 willingness to pay for healthcare services: a meta-analysis","volume":"58","author":"Chaikumbung","year":"2021","journal-title":"Inquiry"},{"issue":"10","key":"10.1016\/j.vhri.2022.08.002_bib46","doi-asserted-by":"crossref","first-page":"567","DOI":"10.36472\/msd.v8i10.616","article-title":"Value in oncology from multi-criteria decision analysis: a systematic review","volume":"8","author":"Guevara-Cuellar","year":"2021","journal-title":"Med Sci Discov"},{"issue":"3","key":"10.1016\/j.vhri.2022.08.002_bib47","first-page":"E298","article-title":"Development of a multicriteria decision analysis framework for evaluating and positioning oncologic treatments in clinical practice","volume":"16","author":"Camps","year":"2020","journal-title":"J\u00a0Oncol Pract"},{"issue":"6","key":"10.1016\/j.vhri.2022.08.002_bib48","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1111\/hex.12178","article-title":"Multicriteria decision analysis in oncology","volume":"18","author":"Adunlin","year":"2015","journal-title":"Health Expect"},{"issue":"5","key":"10.1016\/j.vhri.2022.08.002_bib49","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s12282-019-00967-2","article-title":"Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy","volume":"26","author":"Lee","year":"2019","journal-title":"Breast Cancer"},{"issue":"2","key":"10.1016\/j.vhri.2022.08.002_bib50","doi-asserted-by":"crossref","first-page":"166","DOI":"10.29271\/jcpsp.2021.02.166","article-title":"Clinical outcomes and prognostic factors in HER-2 positive breast cancer with brain metastasis: a single-centre experience","volume":"31","author":"Karakaya","year":"2021","journal-title":"J\u00a0Coll Physicians Surg Pak"},{"issue":"3","key":"10.1016\/j.vhri.2022.08.002_bib51","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/1078155220924088","article-title":"Prognostic factors of ado-trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer","volume":"27","author":"Tataroglu Ozyukseler","year":"2021","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.vhri.2022.08.002_bib52","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1200\/EDBK_323523","article-title":"Immune-based cancer treatment: addressing disparities in access and outcomes","volume":"41","author":"Osarogiagbon","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"8","key":"10.1016\/j.vhri.2022.08.002_bib53","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114393","article-title":"Immunological barriers to immunotherapy in primary and metastatic breast cancer","volume":"13","author":"De Martino","year":"2021","journal-title":"EMBO Mol Med"},{"issue":"4","key":"10.1016\/j.vhri.2022.08.002_bib54","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/0272989X16670604","article-title":"Extrapolation of survival curves from cancer trials using external information","volume":"37","author":"Guyot","year":"2017","journal-title":"Med Decis Making"},{"issue":"6","key":"10.1016\/j.vhri.2022.08.002_bib55","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data: inconsistencies, limitations, and a practical guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Making"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109922001443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109922001443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:13:37Z","timestamp":1761941617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109922001443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":43,"alternative-id":["S2212109922001443"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2022.08.002","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of Pertuzumab Plus Trastuzumab and Docetaxel Compared With Trastuzumab and Docetaxel in the Adjuvant Treatment of Human Epidermal Growth Factor Receptor 2\u2013Positive Metastatic Breast Cancer in Colombia","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2022.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}